Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 0.62 |
| ▸ | BCL2 | P10415 | 16/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.61 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1955748 | 0.90 | BCL2L1 (0.59) | BCL2L1BCL2MCL1 | |
| SCHEMBL29588137 | 0.88 | BCL2L1 (0.56) | BCL2L1BCL2MCL1 | |
| SCHEMBL29855685 | 0.85 | BCL2L1 (0.58) | BCL2L1BCL2MCL1 | |
| SCHEMBL30112833 | 0.84 | BCL2L1 (0.68) | BCL2L1BCL2MCL1 | |
| SCHEMBL30622006 | 0.83 | BCL2L1 (0.54) | BCL2L1BCL2MCL1 | |
| SCHEMBL29644474 | 0.83 | BCL2L1 (0.54) | BCL2L1BCL2MCL1 | |
| SCHEMBL1960922 | 0.83 | BCL2L1 (0.66) | BCL2L1BCL2MCL1 | |
| SCHEMBL30112845 | 0.83 | BCL2L1 (0.66) | BCL2L1BCL2MCL1 | |
| SCHEMBL14655243 | 0.82 | MAPT (0.59) | BCL2L1BCL2MCL1BAK1 | |
| SCHEMBL30112966 | 0.81 | MAPT (0.51) | BCL2L1BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | BCL2, HDAC1, HDAC3 | BCL2L1 22/4885BCL2 1/4885MCL1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.